Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
86.6M
-
Number of holders
-
2
-
Total 13F shares, excl. options
-
174K
-
Shares change
-
-66.9K
-
Total reported value, excl. options
-
$3.76M
-
Value change
-
-$348K
-
Number of buys
-
1
-
Number of sells
-
-2
-
Price
-
$21.61
Significant Holders of Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX) as of Q4 2023
3 filings reported holding SNDX - Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share as of Q4 2023.
Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX) has 2 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 174K shares
of 86.6M outstanding shares and own 0.2% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (7.59M shares), BlackRock Inc. (7.02M shares), Kynam Capital Management, LP (5.66M shares), STATE STREET CORP (5.02M shares), VANGUARD GROUP INC (4.34M shares), Avoro Capital Advisors LLC (4.22M shares), Avidity Partners Management LP (3.95M shares), Eversept Partners, LP (3.38M shares), Point72 Asset Management, L.P. (2.83M shares), and T. Rowe Price Investment Management, Inc. (2.71M shares).
This table shows the top 2 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.